Results 1 to 10 of about 282,868 (219)

Molecular Markers in Guiding Lung Cancer Diagnosis and Treatment

Journal of Men's Health, 2022
Background: Lung cancer has the highest mortality rates and one of the lowest 5-year survival rates amongst cancer types in the world. Although there are constant advancements in treatment, the overall prognosis for lung cancer continues to be poor.
Vivian Li, Wickii T. Vigneswaran
doaj   +1 more source

Transcriptomic Analysis of Papillary Thyroid Cancer: A Focus on Immune-Subtyping, Oncogenic Fusion, and Recurrence [PDF]

Clinical and Experimental Otorhinolaryngology, 2022
Objectives Thyroid cancer is the most common endocrine tumor, with rapidly increasing incidence worldwide. However, its transcriptomic characteristics associated with immunological signatures, driver fusions, and recurrence markers remain unclear.
Seung-Jin Park, Yea Eun Kang, Jeong-Hwan Kim, Jong-Lyul Park, Seon-Kyu Kim, Seung-Woo Baek, In Sun Chu, Shinae Yi, Seong Eun Lee, Young Joo Park, Eun-Jae Chung, Jin Man Kim, Hye Mi Ko, Je-Ryong Kim, Seung-Nam Jung, Ho-Ryun Won, Jae Won Chang, Bon Seok Koo, Seon-Young Kim   +18 more
doaj   +1 more source

Current status and progress in immunotherapy for malignant pleural mesothelioma

Chronic Diseases and Translational Medicine, 2022
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignant disease. Currently, the platinum doublet of pemetrexed and cisplatin is the standard first‐line treatment for unresectable MPM.
Boyang Sun, Yiting Dong, Jiachen Xu, Zhijie Wang   +3 more
doaj   +1 more source

Comprehensive Analysis of CDCAs Methylation and Immune Infiltrates in Hepatocellular Carcinoma

Frontiers in Oncology, 2021
BackgroundAs essential components of cycle growth, the cell division cycle-associated family genes (CDCAs) have crucial roles in tumor development and progression, especially in hepatocellular carcinoma (HCC).
Yongkang Wang, Yinfeng Yang, Yinfeng Yang, Honglei Gao, Ting Ouyang, Luyao Zhang, Jili Hu, Sheng Hu, Hongxing Kan, Hongxing Kan   +9 more
doaj   +1 more source

High‐grade serous peritoneal cancer follows a high stromal response signature and shows worse outcome than ovarian cancer

Molecular Oncology, 2021
In the era of personalized medicine, where transition from organ‐based to individualized genetic diagnosis takes place, the tailoring of treatment in cancer becomes increasingly important.
Francis Jacob, Rosa Lina Marchetti, André B. Kind, Kenneth Russell, Andreas Schoetzau, Viola A. Heinzelmann‐Schwarz   +5 more
doaj   +1 more source

Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment

Molecular Oncology, 2021
Circulating cell‐free DNA (cfDNA) contains circulating tumor DNA (ctDNA), which can be obtained from serial liquid biopsies to enable tumor genome analysis throughout the course of treatment. We investigated cfDNA and mutant ctDNA as potential biomarkers
Brice Pastor, Thierry André, Julie Henriques, Isabelle Trouilloud, Christophe Tournigand, Marine Jary, Thibault Mazard, Christophe Louvet, Simon Azan, Audrey Bauer, Benoit Roch, Cynthia Sanchez, Dewi Vernerey, Alain R. Thierry, Antoine Adenis   +14 more
doaj   +1 more source

Fecal microbiota as a predictor of acupuncture responses in patients with postpartum depressive disorder

Frontiers in Cellular and Infection Microbiology, 2023
BackgroundThere are several clinical and molecular predictors of responses to antidepressant therapy. However, these markers are either too subjective or complex for clinical use. The gut microbiota could provide an easily accessible set of biomarkers to
Yu-Mei Zhou, Jin-Jun Yuan, Yu-Qin Xu, Yan-Hua Gou, Yannas Y. X. Zhu, Chen Chen, Xing-Xian Huang, Xiao-Ming Ma, Min- Pi, Zhuo-Xin Yang   +9 more
doaj   +1 more source

Aberrantly expressed long noncoding RNAs as potential prognostic biomarkers in newly diagnosed multiple myeloma: A systemic review and meta‐analysis

Cancer Medicine, 2023
Background Numerous studies have manifested long noncoding RNAs (lncRNAs) as biomarkers to determine the prognosis of multiple myeloma (MM) patients. Nevertheless, the prognostic role of lncRNAs in MM is still ambiguous.
Jiading Qin, Bo Ke, Tingting Liu, Chunfang Kong, Anna Li, Huan Fu, Chenghao Jin   +6 more
doaj   +1 more source

Progress and Challenges of Immunotherapy Predictive Biomarkers for Triple Negative Breast Cancer in the Era of Single-Cell Multi-Omics

Life, 2023
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with a poor prognosis. Despite conventional treatments, including surgery, radiation, and chemotherapy, the overall response rate to PD-1/PD-L1 immune checkpoint ...
Jiangnan Yu, Zhikun Guo, Lei Wang
doaj   +1 more source

IgE-Mediated Peanut Allergy: Current and Novel Predictive Biomarkers for Clinical Phenotypes Using Multi-Omics Approaches

Frontiers in Immunology, 2021
Food allergy is a collective term for several immune-mediated responses to food. IgE-mediated food allergy is the best-known subtype. The patients present with a marked diversity of clinical profiles including symptomatic manifestations, threshold ...
Rebecca Czolk, Rebecca Czolk, Julia Klueber, Julia Klueber, Martin Sørensen, Martin Sørensen, Paul Wilmes, Françoise Codreanu-Morel, Per Stahl Skov, Per Stahl Skov, Per Stahl Skov, Christiane Hilger, Carsten Bindslev-Jensen, Markus Ollert, Markus Ollert, Annette Kuehn   +15 more
doaj   +1 more source